Pharmacology of the Cardiovascular and Central Nervous Systems

111.    The following drug interactions may occur in patients with monoamine oxidase (MAO) inhibitors:

a.     hypertension after administration of L-dopa.

b.     antagonism of the hypotensive actions of guethidine.

c.     a hypotensive response following ingestion of foods containing tyramine. 

d.     a decreased response to tolbutamide.

e.     potentiation and prolongation of the action of pethidine.

112.    Tricyclic antidepressants such as imipramine:

a.     are free of adverse effects on the heart.

b.     can cause convulsions.

c.     are routinely used in conjunction with MAO inhibitors in the treatment of endogenous depression.

d.     can cause dry mouth and blurred vision.

e.     can cause postural hypotension.

113.    Methylxanthines:

a.     can have an arousing effect in the CNS.

b.     can increase intracellular levels of cAMP.

c.     compete for adenosine-binding sites.

d.     include aminophylline which causes bronchodilation.

e.     decrease calcium entry into intracellular stores.

114.   The following act as dopamine-receptor agonists:

a.      metoclopramide.

b.      fluphenazine decanoate.

c.      bromocriptine.

d.      benztropine.

e.      amantidine.

115.    Blockade of dopamine receptors:

a.      can be an effective treatment for psychotic conditions.

b.      occurs with haloperidol.

c.      can lead to infertility.

d.      can cause a Parkinsonian syndrome.

e.      is an effective treatment of depression.

116.    Vomiting can be caused by:

a.      blockade of dopamine receptors in the chemoreceptor trigger zone.

b.      metoclopramide.

c.      ipecacuanha.

d.      5-HT3 antagonists.

e.      naloxone.

117.    Dopa decarboxylase:

a.      is present in adrenergic fibers.

b.      catalyzes the conversion of trytophan to tyramine.

c.      catalyzes the conversion of 5-hydroxytryptophan to serotonin.

d.      converts levodopa to dopamine.

e.      is inhibited by benserazide. 

118.    When L-dopa is used in the treatment of Parkinson's disease it:

a.      has useful anti-emetic activity.

b.      may be combined with carbidopa to reduce metabolism of L-dopa outside the brain.

c.      is converted to a false transmitter.

d.      can cause psychotic behavior.

e.      is actively taken up by dopaminergic neurons in the CNS.

119.    The following drugs, by affecting dopaminergic mechanisms, can have the actions indicated:

a.      neuroleptics can induce akathesia.

b.      reserpine can alleviate the symptoms of Parkinson's disease.

c.      chlorpromazine can bring about tardive dyskinesia.

d.      chlorpromazine can be used to treat tardive dyskinesia.

e.      mazindol has anorectic activity.

120.    Chlorpromazine:

a.      is used to treat Parkinson's disease.

b.      causes a dry mouth.

c.      causes urinary retention.

d.      causes gynaecomastia.

e.      is a useful appetite suppressant.

<< Last Page                       Answers                             Next Page >>